CrossrefInfokarte
Reflections on adjuvant pembrolizumab for triple-negative breast cancer treated with the KEYNOTE-522 regimen: Is it really necessary?
European Journal of Cancer · 2026-11 · 248 · 117064
DOI: 10.1016/j.ejca.2026.117064 ↗Abstract
Kein Abstract verfügbar.
EUVIMED